Parabilis eyes $475m IPO to push lead asset into Phase III
Parabilis Medicines is hoping to raise $475m in an initial public offering (IPO) as it set its sights on the …
Post
-
-
ASCO26 Podcast: an analyst rundown of the best readouts and key trends
While the 2026 American Society of Clinical Oncology (ASCO) conference may be over for another year, the editorial team at …
-
Pfizer signs licence agreement with Chai for AI drug discovery
Pfizer and Chai Discovery have agreed on a licensing deal enabling the former to incorporate Chai’s AI platform into its …
-
Biogen’s salanersen gains FDA breakthrough therapy designation for SMA
Biogen has received the breakthrough therapy designation from the US Food and Drug Administration (FDA) for salanersen (BIIB115), an investigational …
-
ASCO26: Solid tumour data readouts outline Merck & Co’s oncology prowess
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting saw the presentation of several abstracts and presentations highlighting the …
-
Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership
Eli Lilly has penned a research collaboration deal with Massachusetts-based biotech, Ascidian Therapeutics, to discover and develop drugs for kidney …
-
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in …
-
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with …
-
US lawmakers reveal policy to curb collaboration with Chinese biotech
Two bipartisan Michigan lawmakers have joined forces to debut new legislation that, if enacted, could significantly suppress dealmaking between Chinese …
-
Contraline secures $92.5m to push male contraceptive into late-stage trials
Contraline has closed a $92.5m Series B financing round to take its topical male contraceptive to late-stage trials – potentially …
-
AbbVie receives EC approval for Aquipta to treat migraine
AbbVie has received approval from the European Commission (EC) for Aquipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, …
-
Roche’s giredestrant secures FDA priority review for breast cancer
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational …
-
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
Several abstracts and data presentations on emerging clinical research in non-small cell lung cancer prompted expert interest and discussion at …
-
ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma
Kelonia Therapeutics presented results for the Phase I inMMyCAR clinical trial (NCT07075185) at the American Society of Clinical Oncology (ASCO) …
-
ASCO26: In vivo oncology approaches continue to show promise
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting …
